Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder

The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jacobsen, Lene Orup, Kreilgard, Bo, Hoeck, Ulla, Kristensen, Helle
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Jacobsen, Lene Orup
Kreilgard, Bo
Hoeck, Ulla
Kristensen, Helle
description The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.
format Patent
fullrecord <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_07008637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>07008637</sourcerecordid><originalsourceid>FETCH-uspatents_grants_070086373</originalsourceid><addsrcrecordid>eNqNjksKAjEQRLNxIeod-gIDgQHHvSgeYPbSJp0YyEe6ewa8vRE8gKsqildFbU2cGat44oI5vwF9STWJEpMHbbmb5lMlQAGsmoayiEPujAOMVBVCY9AngTKhlm_SArSVGJ2mleCR0ff5vdkEzEKHn-4MXC_z-TYs8kLtNbnH_qSLnaw9Hcdp_AP5APayQb8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder</title><source>USPTO Issued Patents</source><creator>Jacobsen, Lene Orup ; Kreilgard, Bo ; Hoeck, Ulla ; Kristensen, Helle</creator><creatorcontrib>Jacobsen, Lene Orup ; Kreilgard, Bo ; Hoeck, Ulla ; Kristensen, Helle ; Pfizer Health AB</creatorcontrib><description>The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.</description><language>eng</language><creationdate>2006</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7008637$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,776,798,881,64012</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7008637$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Jacobsen, Lene Orup</creatorcontrib><creatorcontrib>Kreilgard, Bo</creatorcontrib><creatorcontrib>Hoeck, Ulla</creatorcontrib><creatorcontrib>Kristensen, Helle</creatorcontrib><creatorcontrib>Pfizer Health AB</creatorcontrib><title>Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder</title><description>The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2006</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNqNjksKAjEQRLNxIeod-gIDgQHHvSgeYPbSJp0YyEe6ewa8vRE8gKsqildFbU2cGat44oI5vwF9STWJEpMHbbmb5lMlQAGsmoayiEPujAOMVBVCY9AngTKhlm_SArSVGJ2mleCR0ff5vdkEzEKHn-4MXC_z-TYs8kLtNbnH_qSLnaw9Hcdp_AP5APayQb8</recordid><startdate>20060307</startdate><enddate>20060307</enddate><creator>Jacobsen, Lene Orup</creator><creator>Kreilgard, Bo</creator><creator>Hoeck, Ulla</creator><creator>Kristensen, Helle</creator><scope>EFH</scope></search><sort><creationdate>20060307</creationdate><title>Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder</title><author>Jacobsen, Lene Orup ; Kreilgard, Bo ; Hoeck, Ulla ; Kristensen, Helle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_070086373</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Jacobsen, Lene Orup</creatorcontrib><creatorcontrib>Kreilgard, Bo</creatorcontrib><creatorcontrib>Hoeck, Ulla</creatorcontrib><creatorcontrib>Kristensen, Helle</creatorcontrib><creatorcontrib>Pfizer Health AB</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Jacobsen, Lene Orup</au><au>Kreilgard, Bo</au><au>Hoeck, Ulla</au><au>Kristensen, Helle</au><aucorp>Pfizer Health AB</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder</title><date>2006-03-07</date><risdate>2006</risdate><abstract>The present invention is drawn to set of formulations of at least one compound selected from tolterodine, salts thereof, prodrugs thereof and/or metabolites thereof, wherein in the set of formulations contains at least one device for transdermal administration and at least one formulation for oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transmucosal administration, in order to achieve an effect against overactive bladder and/or symptoms associated with this condition. The present invention is further drawn to methods of treating an overactive bladder with the formulations.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_uspatents_grants_07008637
source USPTO Issued Patents
title Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T11%3A18%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Jacobsen,%20Lene%20Orup&rft.aucorp=Pfizer%20Health%20AB&rft.date=2006-03-07&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E07008637%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true